Purpose of this study is evaluation of the effect of compound "Ma-ol-asal" on clinical manifestation of the pediatric asthma in children 6-16 years old that is referred to the pulmonary clinic of the Mofid Children's Hospital in 2015.This study is a randomized clinical trial. Inclusion criteria: patients with asthma 6-16 years old that is referred to the pulmonary clinic of the Mofid Children's Hospital(Tehran, Iran) and patients who are willing and consent to participate in the study. Exclusion criteria: patients under 6 and over 16 years old; patients with moderate asthma; patients with severe asthma; patients requiring hospitalization and patients who have attack; patients with underlying diseases such as CF, Bronchopulmonary dysplasia, heart failure, bronchotracheomalacia, GERD, bronchiectasis, Pulmonary embolism and sarcoidosis; patients who are taking medications such as aspirin, beta blocker and NSAID's; patients who become affected to other acute disease during the study. Patients who are allergic to any components of compound "Ma-ol-asal" and patients who have decision to excluded from the study. This study includes 80 Patients. In this study After taking a history of the patient, all the selected cases were carefully examined, completed a Asthma Control Questionnaire (ACQ), performed spirometry and records were maintained. The classic treatment of asthma was performed for both groups, which include the use of fluticasone spray 50 mcg 2 puffs every 12 hours and salbutamol that was used in cases of exacerbated their symptoms. In addition to the aforementioned treatment, the experimental group also receive compound "Ma-ol-asal". Dosage of the compound "Ma-ol-asal" is 10 ml with 100 ml tepid water, three times a day. Time study is 8 weeks.